Recently, the "List of Guangdong Provincial Engineering Technology Research Centers for 2024" by the Guangdong Science and Technology Department (hereinafter referred to as: Provincial Engineering Center) concluded its public announcement. The "Guangdong AI+BT Microbiome Engineering Technology Research Center," established by Xbiome Co. Ltd., has been successfully recognized as a Provincial Engineering Center.
It is reported that the qualification certification of "Guangdong Provincial Engineering Technology Research Center" plays an important role in the province's scientific and technological innovation system, serving as a crucial means to promote industrial technological progress and accelerate the transformation of scientific and technological achievements. The provincial engineering center focuses on cutting-edge technologies and emerging industries, aiming to cultivate and support a group of engineering technology research centers with strong innovation capabilities and high R&D standards, driving technological upgrades and innovative development in related industries. This initiative has a profound impact on Guangdong Province’s economic development and technological innovation.
The evaluation criteria for provincial engineering centers are strict. Enterprises applying must demonstrate their strength and achievements in scientific research, including research teams, R&D investment, patents, etc., as well as show outstanding capabilities in technological innovation, achievement transformation, and industrial application. Xbiome stood out among numerous applicants, reflecting the high recognition of the company's intestinal microbiology research and innovation capabilities.
In the field of microbiome drug research, Xbiome's latest clinical progress continues to set new milestones for microbiome pharmaceuticals in China and even Asia. The drug code-named XBI-302, a fecal microbiota transplantation (FMT) drug, is the first microbiome drug in Asia to receive clinical approval (IND) from the U.S. FDA and has now successfully entered phase II clinical trials. The drug code-named LBP01 is the first genetically engineered microbial drug in China to enter phase II clinical trials. (Source: Informa Pharma Intelligence, official website of China's National Medical Products Administration)
In the process of industrialization, Xbiome has also achieved outstanding results. In terms of Fecal Microbiota Transplantation (FMT) medical technology, Xbiome's independently developed AI+FMT Precision Microbiota Transplantation Solution can provide comprehensive and personalized gut microbiota transplantation solutions for patients with chronic diseases and sub-healthy populations. In the field of probiotics, Xbiome possesses proprietary functional strains with intellectual property rights, covering functions such as gut health, mental health, and weight management. These have been gradually patented and developed into probiotic products for the market. Xbiome actively engages in probiotic research cooperation with leading domestic and international probiotic companies like WonderLab, and their academic achievements have been continuously published in internationally renowned journals.
With its outstanding innovation in functional strain research, development, and transformation capabilities, Xbiome has established multi-dimensional cooperation in scientific research, R&D, and commercialization with globally renowned probiotic companies such as IFF and ZoHealth, as well as leading enterprises headquartered in Guangdong Province like Mead Johnson China and WonderLab. This strongly supports the development of Guangdong Province's health industry and paves the way for high-quality scientific and technological achievements within the province to reach international markets.
This official recognition as a provincial engineering center is a high endorsement of Xbiome's scientific research capabilities and innovation. The Guangdong Provincial AI+BT Microbiome Engineering Technology Research Center, established by Xbiome, will continue to focus on AI+BT, further increase R&D investment, and accelerate the achievement and industrial transformation of significant breakthrough results. At the same time, the center will be dedicated to the research and application of cutting-edge technologies such as high-throughput sequencing, gene editing, and bioinformatics, promoting the transformation and upgrading of industries like biomedicine and healthcare.
The center looks forward to fully playing its role as an industry demonstrator and leader, providing strong support for the advancement of the Guangdong-Hong Kong-Macao Greater Bay Area's international science and technology innovation center and the construction of a technology powerhouse province, and bringing benefits to patients and the public.
-End-